As Daewoong Pharmaceutical's botulinum toxin product Nabota (Jubo·Jeubeau) is likely to surpass 100 billion won in sales this year, it is drawing attention as it is expanding its global scope as a representative K-toxin product.

Nabota, which was launched in Korea in 2014, recorded 15.1 billion won in 2019 It achieved sales of 79.6 billion won last year after Quantum Jump, 233% sales of 50.4 billion won the following year. After the FDA approved the final item license in February 2019, it began to target the North American market in May of the same year. The U.S. occupies 50% of the global toxin market worth 6 trillion won, and Allergan Botox products are leading the treatment, beauty, and plastic surg